Follow
AegirBio AB
Spotlight (Sweden)
Aegirbio is a precision medicine company. We are focused on therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. Biologic drug concentrations vary widely between patients, leading to unnecessary side effects and suboptimal clinical outcomes. By tracking drug levels in individual patients, these high cost treatments can be personalized to improve treatment results and unlock savings for healthcare systems. Aegirbio is setting new standards in this field by pionee Aegirbio is a precision medicine company. We are focused on therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. Biologic drug concentrations vary widely between patients, leading to unnecessary side effects and suboptimal clinical outcomes. By tracking drug levels in individual patients, these high cost treatments can be personalized to improve treatment results and unlock savings for healthcare systems. Aegirbio is setting new standards in this field by pioneering Point of Care and Point of Need tests that can provide results within minutes.

Read more

Sector:
HEALTH CARE
Current instruments
News
Nothing to display for this company
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
Spotlight
Sweden (SE)
Details of share in AegirBio AB with ticker
Status
Active
Order book id
Amount of instruments
Par value
Market cap
Currency
SEK
Terms
Type
Price
Pre-money valuation
Time
Files
Listing
2020
-
Direct listing of AegirBio AB on Spotlight
Market
Spotlight
Status
Upcoming
Comments for listing & related information
AegirBio plans to do an IPO and get listed on Spotligth during the first half of 2020.

Update: In the middle of January 2020 AegirBio did a pre-IPO of 4.5 MSEK at a pre-money valuation of 70 MSEK.

“With the resources from this Pre-IPO, we are now moving ahead with the listing on Spotlight Markets during the first half of the year. The team in the US can focus on the logistics required to get the Tysabri sample volumes up and of course the work of recruiting new customers. In Europe, our focus will be to produce the first tests on the MagniaReader platform,” Anders Ingvarsson, CEO of LifeAssays AB and acting CEO at Aegirbio, said.
People
Anders Ingvarsson
Chairman of the board
Martin Linde
Board member
Bradley Messmer
Board member
Company Details
Sector
HEALTH CARE
Website

Address
Sölvegatan 43 A
Zip code
223 70
City/district
Lund
Country
Sweden (SE)
Registration number
5592222953
LEI code
First trade date
Registration date
14 Oct 2019
Short name
AegirBio

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date